Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

328
Delayed Quote. Delayed Euronext Bruxelles - 05/22 11:35:03 am
64.54 EUR   +3.20%
05/04 UCB : ex-dividend day for annual dividend
04/02 DR REDDY LABORA : Labs to Acquire Brands Portfolio of UCB for USD128..
03/30 Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 billion
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
62.71(c) 63.05(c) 62.4(c) 62.54(c) 64.54(c) Last
229 120 266 327 195 652 278 554 517 712 Volume
+0.48% +0.54% -1.03% +0.22% +3.20% Change
More quotes
Financials (€)
Sales 2015 3 655 M
EBIT 2015 522 M
Net income 2015 285 M
Debt 2015 1 509 M
Yield 2015 1,80%
Sales 2016 3 943 M
EBIT 2016 669 M
Net income 2016 392 M
Debt 2016 1 335 M
Yield 2016 1,94%
PER 2015 40,74
PER 2016 29,94
EV / Sales 2015 3,85x
EV / Sales 2016 3,52x
Capitalization 12 553 M
More Financials
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
07/30Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
05/04 UCB : ex-dividend day for annual dividend
04/02 DR REDDY LABORATORIES : Labs to Acquire Brands Portfolio of UCB for USD128 Milli..
03/30 Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 billion
03/27 UCB : Convening notice to attend the general meeting of shareholders
03/25 UCB : Findings from UCB Pharma SA Yields New Findings on Toxicology (Identificat..
02/12 UCB : Patent Issued for Systems for Administering Medication
02/12 UCB : Patent Issued for Syringe Safety Assembly
01/28 UCB : announces US and EU regulatory filings for the investigational antiepilept..
More news
Sector news : Biopharmaceuticals
07:39a GERMANY'S MERCK EXPECTS DRUG DIVISIO : Euro am Sonntag
05/22DJAmgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update
05/22 AMGEN : ends work on experimental psoriasis drug
More sector news : Biopharmaceuticals
News from SeekingAlpha
02/08 WEEK IN REVIEW : WuXi NextCode Leads $15 Million Financing In Claritas Genomics


Comments 
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions